This revelation builds upon over a decade of rigorous research aiming to harness mRNA therapeutics’ ability to stimulate the immune system to combat malignancies. The COVID-19 mRNA vaccines, initially designed to teach the immune system to recognize and respond to the SARS-CoV-2 spike protein, may have an unexpected broader impact. The study analyzed comprehensive patient records and found that the mRNA vaccine could “wake up” and sensitize tumors to immunotherapy, greatly enhancing antitumor immune responses and extending patient survival times compared to immunotherapy alone.

Data analysis encompassed over 1,000 patients treated at MD Anderson from 2019 to 2023, focusing on individuals with stage 3 and 4 non-small cell lung cancer as well as metastatic melanoma. Among these, patients receiving the COVID-19 mRNA vaccine soon before or after initiating immunotherapy had nearly double the median survival in lung cancer—from 20.6 months to 37.3 months—and a considerable extension in survival among melanoma patients, underscoring the vaccine’s potential as a powerful adjunct to existing treatments.

At the core of this discovery lies the mechanism of immune checkpoint blockade, wherein therapeutic agents release the natural “brakes” on T cells, enabling a more vigorous attack on cancer cells. Historically, many patients show limited responses to these therapies. However, the introduction of an mRNA vaccine appears to act as an immune system primer, inflaming immunologically “cold” tumors and mobilizing immune cells from tumorous environments to lymph nodes, facilitating a robust antitumor response.

Dr. Elias Sayour, a pediatric oncologist at UF and co-senior author of the study, has extensively investigated mRNA vaccines from a nontraditional angle. His past work demonstrated that a so-called “nonspecific” mRNA vaccine, not targeting any specific tumor antigens but based on mRNA technology, could generate potent antitumor immunity in preclinical models. This concept challenged the longstanding paradigm that vaccines must target particular tumor markers, instead leveraging the immune system’s virus-fighting machinery to attack cancers broadly.

To probe whether the widely administered COVID-19 mRNA vaccines might exert similar off-target immunomodulatory effects, the research team assessed clinical outcomes of patients receiving these vaccines in proximity to immune checkpoint therapy initiation. Complementing clinical data, murine studies using COVID spike-targeted mRNA vaccines combined with checkpoint inhibitors demonstrated that previously resistant tumors could be rendered susceptible, suppressing tumor growth and substantially improving survival.

The implications of this work are profound. Not only could existing COVID-19 mRNA vaccines inadvertently confer therapeutic benefits for cancer patients undergoing immunotherapy, but it also opens the door for engineered “universal” mRNA vaccines designed explicitly to prime and enhance immune responses against various cancers. Such vaccines would be “off-the-shelf,” broadly applicable across cancer types, and could be rapidly deployed, revolutionizing standard oncological care.

While the evidence is compelling, the authors caution that the findings remain observational and urge rigorous randomized clinical trials to validate efficacy and causality. Plans are underway to initiate such a trial through the OneFlorida+ Clinical Research Network, which spans multiple states and healthcare institutions, setting a path toward translating these discoveries from academic settings into widespread clinical practice.

Experts in the field have hailed the study as a striking example of how mRNA technology, propelled into the spotlight by the COVID-19 pandemic, continues to reveal unforeseen benefits beyond infectious disease prevention. Dr. Jeff Coller of Johns Hopkins University remarked that this study exemplifies how innovative mRNA medicines are revolutionizing cancer treatment, a field long in need of breakthroughs.

In advanced cancers, where therapeutic options are often exhausted and prognoses grim, the possibility of extending survival by leveraging the immune system’s innate defenses via mRNA vaccines is a beacon of hope. A universal cancer vaccine that synergizes seamlessly with immunotherapy could represent a paradigm shift, transforming cancer from a terminal diagnosis to a manageable chronic disease or even achieving long-term remission.

Additionally, the study found no survival benefit from non-mRNA vaccines such as flu or pneumonia vaccines, underscoring the unique immunological properties of mRNA platforms. This specificity hints at the distinctive molecular and cellular pathways engaged by mRNA vaccines, which may effectively recalibrate the immune milieu surrounding tumors to overcome resistance barriers.

The successful application of mRNA vaccines in oncology is the culmination of technological advances in lipid nanoparticle delivery systems and a deeper understanding of mRNA biology. These innovations enable the precise delivery and sustained expression of therapeutic proteins or immunostimulatory signals, energizing immune cells without triggering deleterious inflammation.

Future directions involve optimizing the design of nonspecific mRNA vaccines to amplify their efficacy and safety profiles. Researchers envision vaccines that rally a broad army of immune effectors, including dendritic cells and cytotoxic T lymphocytes, thereby enhancing tumor antigen presentation and immune memory formation, critical components for durable cancer control.

With extensive patent portfolios related to UF-developed mRNA vaccines licensed to biotechnology enterprises, the translation of this research into commercially viable therapies is actively progressing. These collaborative efforts between academia and industry aim to rapidly bring next-generation cancer vaccines to the clinic, fundamentally altering therapeutic paradigms.

Ultimately, this discovery underscores the untapped potential of mRNA vaccine technology far beyond infectious diseases, heralding a new era where immunotherapy and vaccination converge to offer cancer patients renewed hope and improved survival outcomes.

Subject of Research: People

Article Title: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade

News Publication Date: 22-Oct-2025

Web References:
https://dx.doi.org/10.1038/s41586-025-09655-y

References:
Sayour, E.J., Grippin, A., and Mitchell, D.A. “SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade.” Nature, 2025.

Image Credits: UF Health/Jackie Hart

Keywords: Cancer, Lung cancer, Skin cancer, Cancer treatments, COVID-19, SARS CoV-2, COVID-19 vaccines, Vaccine research

Patients with advanced lung or skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer than those who did not get the vaccine, researchers have found.

The observation by researchers at the University of Florida and the University of Texas MD Anderson Cancer Center is a defining moment in a decade-plus of research testing mRNA-based therapeutics designed to “wake up” the immune system against cancer. Building on a previous UF study, the observation also marks a significant step toward a long-awaited universal cancer vaccine to boost the tumor-fighting effects of immunotherapy.

The findings from an analysis of more than 1,000 patients’ records at MD Anderson are preliminary, but if validated in a randomized clinical trial now in design, the study could have a widespread clinical impact.

“The implications are extraordinary — this could revolutionize the entire field of oncologic care,” said senior researcher Elias Sayour, M.D., Ph.D., a UF Health pediatric oncologist and the Stop Children’s Cancer/Bonnie R. Freeman Professor for Pediatric Oncology Research. “We could design an even better nonspecific vaccine to mobilize and reset the immune response, in a way that could essentially be a universal, off-the-shelf cancer vaccine for all cancer patients.”

Jeff Coller, Ph.D., a leading mRNA scientist and professor at Johns Hopkins University, said the findings point to yet another way Operation Warp Speed — part of the federal government’s early response to COVID-19 — continues to save Americans’ lives in “unique and unexpected ways.”

“The results from this study demonstrate how powerful mRNA medicines truly are and that they are revolutionizing our treatment of cancer,” Coller said.

Presented today at the 2025 European Society for Medical Oncology Congress in Berlin, the findings build upon Sayour’s eight years of work combining lipid nanoparticles and mRNA. Short for messenger RNA, mRNA molecules are found in every cell and carry the genetic information needed to make proteins.

Notably, Sayour’s lab reported a surprising finding in July: to prompt a strong antitumor reaction, they needn’t go after a specific target protein in a tumor; instead, they could simply rev up the immune system — as if fighting a virus.

Like a one-two punch, pairing Sayour’s patented experimental “nonspecific” mRNA vaccine with common anticancer drugs called immune checkpoint inhibitors triggered a strong antitumor response in lab mice. The experimental vaccine was nonspecific to COVID spike protein or any other virus or cancer but rooted in similar technology to the COVID vaccines.

That discovery, years in the making, sparked a question from former lab member and lead researcher Adam Grippin, M.D., Ph.D., who trained at UF’s Preston A. Wells Center for Brain Tumor Therapy and now works at MD Anderson.

Would the COVID-19 mRNA vaccine work like the nonspecific vaccine?

To find out, the research team analyzed existing data from patients with Stage 3 and 4 non-small cell lung cancer and metastatic melanoma treated at MD Anderson from 2019 to 2023.

What they found was that receiving a COVID mRNA vaccine within 100 days of starting immunotherapy drugs was associated with living longer by a significant amount.

The most dramatic difference, Sayour said, was in patients not expected to have a strong immune response, based on their tumors’ molecular makeup and other factors.

As with any observational study, the findings require confirmation from a prospective and randomized clinical trial.

Nonetheless, the discovery is pivotal.

“Although not yet proven to be causal, this is the type of treatment benefit that we strive for and hope to see with therapeutic interventions — but rarely do,” said Duane Mitchell, M.D., Ph.D., Grippin’s doctoral mentor and director of the UF Clinical and Translational Science Institute. “I think the urgency and importance of doing the confirmatory work can’t be overstated.”

In lung and skin cancers, doctors commonly engage the immune system with drugs designed to “release the brakes” and recognize and attack cancer cells more effectively. In advanced disease stages, however, most patients don’t respond well and often have exhausted other treatment options like radiation, surgery and chemotherapy.

The new study involved records of 180 advanced lung cancer patients who received a COVID vaccine within a 100-day period before or after starting immunotherapy drugs and 704 treated with the same drugs who did not receive the vaccine. Getting the vaccine was associated with a near doubling of median survival, from 20.6 months to 37.3 months.

Of the metastatic melanoma patients, 43 received a vaccine within 100 days of initiating immunotherapy, while 167 patients did not receive a vaccine. With the vaccine, median survival increased from 26.7 months to a range of 30 to 40 months; at the time the data were collected, some patients were still alive, meaning the vaccine effect could be even stronger.

Receiving non-mRNA pneumonia or flu vaccines resulted in no changes in longevity.

To back their findings, UF researchers then used mouse models to pair immunotherapy drugs with an mRNA vaccine targeted specifically at COVID spike protein. Those experiments showed they could turn unresponsive cancers into responsive ones, thwarting tumor growth.

“One of the mechanisms for how this works is when you give an mRNA vaccine, that acts as a flare that starts moving all of these immune cells from bad areas like the tumor to good areas like the lymph nodes,” Sayour said.

The next step is to launch a large clinical trial through the UF-led OneFlorida+ Clinical Research Network, a consortium of hospitals, health centers and clinics in Florida, Alabama, Georgia, Arkansas, California and Minnesota.

“One of our key motivations at OneFlorida is to move discoveries from academic settings out into the real world and the places where patients get care,” said Betsy Shenkman, Ph.D., who leads the consortium.

If confirmed, the new findings unlock numerous possibilities, and the researchers said an even better nonspecific universal vaccine could be designed. For patients with advanced cancers, the increased survival from such a universal vaccine could provide a priceless benefit: more time.

“If this can double what we’re achieving currently, or even incrementally — 5%, 10% — that means a lot to those patients, especially if this can be leveraged across different cancers for different patients,” said Sayour, an investigator with UF’s McKnight Brain Institute.

The study was funded by the National Cancer Institute and multiple foundations. 

Sayour, Grippin and Mitchell hold patents related to UF-developed mRNA vaccines that are licensed by iOncologi Inc., a biotech company born as a “spinout” from UF in which Mitchell holds interest.

Meeting

ESMO Congress 2025